Temozolomide desensitization followed by metronomic dosing in patients with hypersensitivity.
Byran J NethMichael W RuffJoon H UhmDerek R JohnsonRohit D DivekarDaniel E MaddoxPublished in: Cancer chemotherapy and pharmacology (2020)
Our results suggest that rapid-desensitization followed by metronomic temozolomide should be considered in patients with glioma who experience hypersensitivity. This strategy provides comparable outcomes to therapy with standard protocols, with the majority of patients able to tolerate temozolomide after desensitization with favorable disease control.